Promising patient trials surrounding this compound, specifically the high-dose formulation branded as ZPHC, suggest a considerable benefit on weight decrease and related metabolic conditions . Experts posit that this dual agonist , affecting both GLP-1 and GIP pathways , could offer a substantia